IPCA Laboratories Limited — Q3 FY26 earnings call

Call held 16 Feb 2026

Management summary

Ipca Labs reported a robust Q3 FY26 with consolidated revenue growth of 6.5% and significant EBITDA margin expansion, driven by strong domestic and export formulation performance. While the API business remained flat and Unichem faced challenges in its US portfolio, management outlined strategies for market share regain and margin improvement, including new product launches and capacity utilization. The company maintains a healthy cash position and is focusing on biosimilar development and green energy initiatives.

Highlights

  • Consolidated business grew 6.5% to ₹2,393 crores in Q3 FY26, and 8.44% to ₹7,258 crores for 9M FY26.

  • Consolidated EBITDA margin improved by 263 bps to 22.5% in Q3 FY26 (vs 19.87% in Q3 FY25).

  • Standalone EBITDA margin improved by 184 bps to 26.09% in Q3 FY26 (vs 24.25% in Q3 FY25).

  • Domestic business grew 12% in Q3 FY26, with chronic segment growing 15% and acute segment 8.4%.

  • Export formulation business grew 17% in Q3 FY26 and 6% for 9M FY26.

  • US business (Ipca + Unichem) grew 17% in Q3 FY26 to ₹395 crores and 15% for 9M FY26 to ₹1,140 crores.

Concerns

  • API business was flat at ₹317 crores in Q3 FY26.

  • Unichem's overall business grew only around 2% in the current financial year due to lost high-volume US business.

  • Unichem's EBITDA margin was around 8% in Q3 FY26.

  • Antimalarial business declined by almost 21% in Q3 FY26.

  • UK business remains fiercely competitive, with products selling at losses, though recovery is now being seen.

Key financials

2 periods

Headline

  • Consolidated Revenue
    ₹2,393 Cr
    YoY +6.5%
  • Consolidated EBITDA Margin
    22.5%
  • Standalone EBITDA Margin
    26.1%

Q3 FY26

  • API Business Revenue
    ₹317 Cr
    YoY 0%

What they filed

Q1 FY27: revenue up 21.3%, net profit up 42.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,811 1,663 1,638 1,747 1,930 +7%1,845 +11%1,814 +11%2,119 +21%
EBITDA402 411 359 407 465 +16%477 +16%431 +20%578 +42%
Net profit244 268 -65 262 305 +25%303 +13%262 +503%373 +42%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentGrowthRevenue
Domestic Business (Q3 FY26)12%—
Export Formulation Business (Q3 FY26)17%—
Export Formulation Business (9M FY26)6%₹1,477 Cr
API Business (9M FY26)14%₹1,051 Cr
Consolidated Business (9M FY26)8.4%₹7,258 Cr
US Business (Ipca + Unichem) (Q3 FY26)17%₹395 Cr
US Business (Ipca + Unichem) (9M FY26)15%₹1,140 Cr

Capital allocation

high confidence
  • Capex ₹50 Cr
    • Solar project for green energy ₹50 Cr
    And currently, there are hardly any expansion plan except some solar project, which is currently going on to use more green energy. And that will have a capital outlook of almost around INR50 crores.
  • Liquidity Cash ₹250 Cr Company has healthy cash flow and is sitting with more than INR250 crores of cash in the bank, despite a payment of INR181 crores for an EU fine.
    Let's say that their cash flow was also impacted because of payment of European Union, that fine which was to be paid on past issue of parent appeal, some issues. So almost around INR181 crores has gone there. So they have healthy cash flow right now. They are sitting with almost around more than INR250 crores of cash in the bank.

Guidance & targets

Profitability

  • Unichem EBITDA Margin Profitability · in 2-3 years · Medium confidence 15%
    EBITDA margin to begin with around 15% maybe in 2, 3 years' time and gradually improve it to about 20% when all their filing and registrations will come in the European market and that business will grow.

    — Harish Kamath

  • Unichem EBITDA Margin Profitability · after 2-3 years · Low confidence 20%

    — Harish Kamath

  • EBITDA Margin Improvement Profitability · per year · Medium confidence 1.5%
    If top line growth is around 10% to 12%, margin will definitely improve by 1.5% plus.

    — Ajit Kumar Jain

  • EBITDA Margin Improvement Profitability · next 2 years · Medium confidence 300 bps
    So there is a potential of 300 basis point margin improvement in the next 2 years provided the growth remains at 10%, 11%?

    — Ajit Kumar Jain

Revenue

  • Unichem Top Line Growth Revenue · over a period of time · Medium confidence 8-10%
    See, once this -- whatever market loss they have in the U.S. gets recovered, then over a period of time, they should grow their top line anywhere between 8% to 10%.

    — Harish Kamath

  • Overall Company Growth Revenue · long term · Medium confidence 10-11%
    So overall the company growth is around 10% to 11%. That is what is the overall broadly.

    — Ajit Kumar Jain

  • Promotional Branded Business Growth Revenue · longer period of time · Medium confidence 10-12%
    So I think, overall, this promotional branded market should continue to have around 10% to 12% kind of growth over a longer period of time.

    — Ajit Kumar Jain

  • Generics Business Growth (Europe, US) Revenue · long term · Medium confidence 10-12%
    So overall generic businesses, we expect similar kind of around 10% to 12% kind of growth.

    — Ajit Kumar Jain

  • API Business Growth Revenue · long term · Low confidence slightly lower
    API business will have a slightly little lower growth.

    — Ajit Kumar Jain

  • Domestic Business Growth Revenue · long term · Medium confidence 10-12%
    And domestic business is also around 10% to 12% kind of growth.

    — Ajit Kumar Jain

Product Pipeline

  • Ipca US Filings Product Pipeline · every year · Medium confidence 5-6 filings
    I think current year, we already made 4 filings. And I think annual basis also, around 5 to 6 filings would happen every year.

    — Ajit Kumar Jain

  • Unichem US New Molecules Product Pipeline · next 2-3 years · Medium confidence 4-5 new molecules
    And another 4 or 5 more Ipca molecule will also get launched in the U.S. market. So Unichem U.S. will also have that benefit going forward.

    — Harish Kamath

  • Ipca US New Molecules (via Unichem) Product Pipeline · next 12-15 months · Medium confidence 5-7 molecules
    Chirag, we have about 35 registrations, out of which 5 we have commercialized. Another 5 to 7 molecules will get commercialized over the next 12 to 15 months.

    — Harish Kamath

What to watch in Q4 FY26

Unichem US market share regain

next 1-2 quarters
Current Lost in 1-2 key molecules
Target Recovery initiated, growth in own portfolio

Why it matters

Recovery of Unichem's US market share is crucial for its overall growth and margin improvement targets.

We will recover that business. It may take another 1 or 2 more quarters.

Risks & concerns

  • Unichem US market share loss

    medium

    Unichem lost market share in 1-2 high-volume molecules in the US due to increased competition and price reduction, impacting overall business growth and margins.

    Management acknowledged

  • UK market competitiveness and losses

    medium

    The UK market was fiercely competitive, leading to products being sold at losses, though a sharp recovery in prices has been observed recently.

    Management acknowledged

  • Antimalarial business decline

    low

    The antimalarial segment declined by almost 21% in Q3 FY26, although other segments performed well.

    Management acknowledged

  • Institutional business uncertainties

    low

    Uncertainties in the institutional business are a factor in overall growth outlook.

    Management acknowledged

Q&A highlights

6 direct
Unichem EBITDA margin roadmap Direct
Improvement in EBITDA margins will come from, let's say, higher utilization of capacity, better U.S. business, which we hope to do in time to come, and also implement the business which is currently happening in Europe.

Management outlined key drivers for Unichem's margin improvement, including capacity utilization and US/European business growth.

Asked by Aanchal Jalan

Land sale proceeds utilization Direct
Let's say that their cash flow was also impacted because of payment of European Union, that fine which was to be paid on past issue of parent appeal, some issues. So almost around INR181 crores has gone there. So they have healthy cash flow right now. They are sitting with almost around more than INR250 crores of cash in the bank.

Clarified the company's strong liquidity position and the impact of a past EU fine, indicating no immediate need for the land sale proceeds for expansion.

Asked by Aanchal Jalan

Promotional brands growth drivers Direct
I think West Africa has done very good business in this quarter. And overall, I think for the whole of the year, which is more of a French-speaking African market and all, that business has grown by almost around 41% for the first 9 months. And in Q3, that has gone up by almost around 69%.

Identified specific geographic regions (West Africa, Latin America, Middle East, East Asia) driving strong growth in promotional brands.

Asked by Surya Narayan Patra

Domestic formulation growth moderation and GLP impact Partial
We are also working for in-licensing so we can come with the GLP. It's not that in-house we will not be manufacturing, but yes, we are looking for those kind of opportunities. And overall, let's say, for us, this growth is going to remain better because the trend, whatever we are seeing, that is better.

Addressed concerns about moderating domestic growth and the company's strategy for GLP products through in-licensing, rather than in-house manufacturing.

Asked by Surya Narayan Patra

Gross margin sustainability and drivers Direct
It's all the product mix change and higher-margin business is growing higher in this quarter that has also resulted in higher margin.

Explained that the improved gross margin is primarily due to a favorable product mix and growth in higher-margin businesses, suggesting sustainability.

Asked by Surya Narayan Patra

Unichem market share loss and recovery plan Direct
We're also launching 4, 5 more molecules in the U.S. market, and we are also taking necessary steps to regain the market share where the market is lost for 2, 3 major molecules. So suddenly, because of increase in the competition and price reduction, they lost some business. So we will recover that business. It may take another 1 or 2 more quarters.

Provided a clear strategy and timeline for Unichem to recover lost market share in the US, involving new launches and competitive actions.

Asked by Dharmil Shah

Ipca US filings and commercialization timeline Partial
It will all depend on approval timeline. But let's say, we have over 30 filings, and we still have around 8, 10 approvals still pending past approval. And thereafter, the new filing approval. So it will all depend on how the filing approvals start coming in.

Indicated a significant number of pending approvals for Ipca's US filings, highlighting regulatory timelines as a key factor for commercialization.

Asked by Sai Om Mukherji

European market pricing recovery Direct
But last 1 month, we have started seeing a sharp recovery again in prices, and the recoveries are as high as 30%, 40% kind of recoveries are seen.

Revealed a recent and significant recovery in pricing in the European market, particularly in the UK, which had previously been a drag on profitability.

Asked by Harsh Bhatia

3 min read 7 chapters

Detailed narrative

Q3 FY26 Financial Performance Overview

Ipca Laboratories reported a consolidated business growth of 6.5% in Q3 FY26, reaching ₹2,393 crores, and an 8.44% growth for the first nine months of FY26, totaling ₹7,258 crores. The consolidated EBITDA margin significantly improved by 263 basis points to 22.5% in Q3 FY26 compared to 19.87% in Q3 FY25. Standalone EBITDA margin also saw an improvement of 184 basis points, reaching 26.09% from 24.25% in the prior year's corresponding quarter.

Domestic and Export Formulation Business Highlights

The domestic business delivered a robust 12% growth in Q3 FY26, outperforming the Indian Pharmaceutical Market (IPM) growth of 8.9%. Within the domestic segment, the chronic business grew by 15% and the acute segment by 8.4%. The company's market share remained at 2.08% as per MAT December 2025. Export formulation business demonstrated strong performance with a 17% growth in Q3 FY26 and a 6% growth for the nine-month period, reaching ₹1,477 crores.

API Business and US Market Performance

The API business remained flat at ₹317 crores in Q3 FY26, though it grew by 14% for the nine-month period to ₹1,051 crores. The combined US business (Ipca and Unichem) showed significant growth, increasing by 17% in Q3 FY26 to ₹395 crores and by 15% for 9M FY26 to ₹1,140 crores. This growth was largely attributed to Ipca's portfolio and the Bayshore portfolio integrated into Unichem.

Unichem Integration and Future Outlook

Unichem's overall business grew only about 2% in the current financial year, primarily due to market share loss in high-volume US products. However, its European business is improving, and the company plans to launch 4-5 more Ipca molecules in the US market over the next 2-3 years. Management targets Unichem's top line to grow 8-10% and its EBITDA margin to improve to 15% in 2-3 years, eventually reaching 20% as filings and registrations in Europe materialize.

EBITDA Margin Drivers and Sustainability

The improvement in EBITDA margins was primarily driven by a favorable product mix and the higher growth of higher-margin businesses. The material cost-to-sales ratio for standalone operations improved by approximately 3.64% in Q3 FY26. Management expects a 1.5% plus annual improvement in EBITDA margins if top-line growth remains in the 10-12% range, with a potential for 300 basis points improvement over the next two years under sustained growth.

Strategic Focus Areas and Capital Allocation

Ipca is focusing on several strategic areas including integrated manufacturing, optimizing US and Unichem integration, and building capabilities in biosimilars. The company currently has 5 biosimilar candidates, with technology transfer initiated for two products. Capital expenditure plans are minimal, with only a ₹50 crore solar project for green energy currently underway. The company maintains a strong liquidity position with over ₹250 crores of cash in the bank, even after paying a ₹181 crore EU fine.

European Market Dynamics and Recovery

The European business, particularly in the UK, has been fiercely competitive, leading to products being sold at losses. However, management noted a sharp recovery in prices in the last month, with recoveries as high as 30-40%. This recovery is expected to improve profitability in this segment, which historically has lower margins compared to other European markets like Scandinavia.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls